Skip to main content
Premium Trial:

Request an Annual Quote

Sema4: Sema4 Elements

Sema4, a molecular diagnostics and clinical data company, has launched Sema4 Elements, a portfolio of genomic tests, digital tools, and services in reproductive health for patients and providers. It includes a new version of the company's Expanded Carrier Screen (ECS) that provides personalized residual risk assessments, its noninvasive prenatal test (NIPT), and its Natalis newborn screen. One of the digital tools in the portfolio is Pregnancy Journey, an educational resource and tracking tool for pregnant women. Services include customized workflows, genetic counseling, and patient-friendly billing policies.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.